OnKure (OKUR) Director R. Michael Carruthers Receives Award

What Happened

• R. Michael Carruthers, a director of OnKure Therapeutics (OKUR), received a grant/award covering 7,650 derivative shares on June 4, 2026. The Form 4 reports an acquisition price of $0.00 (this is an award/derivative grant, not a cash purchase or sale).

Key Details

• Transaction date: 2026-06-04; Form 4 filed: 2026-06-08.
• Transaction type/code: Award/Grant (A) of derivative securities (7,650 shares); acquisition price reported $0.00.
• Vesting: 100% vests on the earlier of June 4, 2027 or the day before the issuer’s next annual meeting, contingent on continued service (per footnote).
• Shares owned after transaction: Not disclosed on the provided summary of the filing.
• Timeliness: Filing date (6/8/2026) appears to be within the usual Form 4 reporting window (filed two business days after the transaction).

Context

• This was a grant/award of derivative securities (likely stock options or restricted stock units) rather than an open-market buy or sale; no immediate exercise or sale occurred. Such awards are common for directors and are primarily a form of compensation that vests over time, and do not by themselves signal a buy or sell decision by the insider.